Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 1/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10508401 | 0.98 | HSD17B10 (0.61) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL10371770 | 0.89 | KLK1 (0.68) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL28543736 | 0.83 | NPC1 (0.65) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL30619961 | 0.83 | NPC1 (0.65) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL10373141 | 0.82 | CYP1A2 (0.52) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL10374498 | 0.80 | CYP1A2 (0.43) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| SCHEMBL1269573 | 0.80 | KLK1 (0.61) | KLK1KLK5HSD17B10PKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL710492 | 0.78 | PKM (0.67) | KLK1KLK5HSD17B10PKMNPC1 | |
| SCHEMBL711507 | 0.78 | PKM (0.71) | KLK1KLK5HSD17B10PKMNPC1 | |
| SCHEMBL31734838 | 0.78 | PKM (0.71) | KLK1KLK5HSD17B10PKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0252507-B1 | 2-(4-PYRIDYLAMINOMETHYL)-BENZIMIDAZOLE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1990-10-10 | — | — | EP | claimed |
| EP-0209106-B1 | 2-(4-PYRIDYLAMINOMETHYL)-BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1989-10-18 | — | — | EP | claimed |
| EP-0252507-A1 | 2-(4-Pyridylaminomethyl)-benzimidazole derivatives having antiviral activity | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1988-01-13 | — | — | EP | claimed |
| US-4714764-A | ENTEROVIRUS AND RHINOVIRUS | MARUISHI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-12-22 | — | — | US | claimed |
| EP-0209106-A1 | 2-(4-Pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1987-01-21 | — | — | EP | claimed |
| JP-63179870-A | — | — | None | — | — | JP | disclosed |
| JP-62016477-A | — | — | None | — | — | JP | disclosed |
| JP-63022091-A | — | — | None | — | — | JP | disclosed |
| US-8231879-B2 | Treatment of diseases caused by viral infection | NIKLASSON BO (SE) | 2012-07-31 | — | — | US | disclosed |
| US-20090004143-A1 | TREATMENT OF DISEASES CAUSED BY VIRAL INFECTION | NIKLASSON BO | 2009-01-01 | — | — | US | disclosed |
| US-7442380-B2 | Administering pleconaril (3-[3,5-dimethyl-4-[[3-(3-methyl-5-isoxazolyl)propyl]oxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole) to human or mammal having diabetes mellitus associated with ljungan virus | APODEMUS AB (SE) | 2008-10-28 | — | — | US | disclosed |
| EP-1596859-B1 | TREATMENT OF DISEASES CAUSED BY LJUNGAN VIRUS BY USING PLECONARIL | APODEMUS AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-4714764-A | ENTEROVIRUS AND RHINOVIRUS | MARUISHI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-12-22 | — | — | US | disclosed |
| US-4714764-A | ENTEROVIRUS AND RHINOVIRUS | MARUISHI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-12-22 | — | — | US | disclosed |
| US-4714764-A | ENTEROVIRUS AND RHINOVIRUS | MARUISHI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-12-22 | — | — | US | disclosed |
| JP-S6216477-A | 2-(4-PYRIDYLAMINOMETHYL)-BENZIMIDAZOLE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | MARUISHI SEIYAKU KK | 1987-01-24 | — | — | JP | disclosed |
| EP-0209106-A1 | 2-(4-Pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1987-01-21 | — | — | EP | disclosed |
| EP-0209106-A1 | 2-(4-Pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1987-01-21 | — | — | EP | disclosed |
| JP-S06216477-A | — | — | 0001-01-01 | — | — | JP | disclosed |
| JP-S06322091-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004143-A1 | TREATMENT OF DISEASES CAUSED BY VIRAL INFECTION | PGF, IFNG, MYOF | KLK1 2278/4885KLK5 2166/4885HSD17B10 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.